Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of DWP16001 Formulations in Healthy Volunteers
NCT05465668Phase 1Completed
- Sponsor
- Daewoong Pharmaceutical
- Start
- Jul 2022
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of enavogliflozin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Daewoong Pharmaceutical. Primary endpoints: Maximum Plasma Concentration and Area Under the Curve to Last Measurable Concentration. Started Jul 2022; status: completed.
02
Drugs
enavogliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05465668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05465668.